Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Fosfocreatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosfocreatine SCHEMBL65425 | 0.89 | MVD (0.44) | MVD | |
| Fosfocreatine SCHEMBL24116748 | 0.89 | MVD (0.44) | MVD | |
| Fosfocreatine SCHEMBL2124030 | 0.89 | MVD (0.44) | MVD | |
| Fosfocreatine SCHEMBL2635002 | 0.87 | MVD (0.42) | MVD | |
| Fosfocreatine SCHEMBL9075223 | 0.81 | MVD (0.39) | MVD | |
| Fosfocreatine SCHEMBL5248692 | 0.81 | MVD (0.39) | MVD | |
| Fosfocreatine SCHEMBL453327 | 0.80 | MVD (0.38) | MVD | |
| Fosfocreatine SCHEMBL29749874 | 0.73 | MVD (0.40) | MVD | |
| Fosfocreatine SCHEMBL2817382 | 0.73 | MVD (0.34) | MVDMEN1LMNAKMT2A | |
| Fosfocreatine SCHEMBL1640494 | 0.72 | MVD (0.38) | MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12543767-B2 | Oral supplements containing enriched phenolic compound extracts combined with organic acid sodium salts, creatines and/or creatine salts | PHENOLICS, LLC | 2026-02-10 | — | — | US | claimed |
| US-20220338519-A1 | ORAL SUPPLEMENTS CONTAINING ENRICHED PHENOLIC COMPOUND EXTRACTS COMBINED WITH ORGANIC ACID SODIUM SALTS, CREATINES AND/OR CREATINE SALTS | PHENOLICS, LLC (US) | 2022-10-27 | — | — | US | claimed |
| EP-4727956-A1 | NOVEL PROTEINS FOR ISOTHERMAL AMPLIFICATION | Diebold Innovation GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-12543767-B2 | Oral supplements containing enriched phenolic compound extracts combined with organic acid sodium salts, creatines and/or creatine salts | PHENOLICS, LLC | 2026-02-10 | — | — | US | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2025038482-A2 | USE OF FISETIN FOR REDUCING THE INCIDENCE OF ATRIAL FIBRILLATION | RHODE ISLAND HOSPITAL (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2024256644-A1 | NOVEL PROTEINS FOR ISOTHERMAL AMPLIFICATION | MIDGE MEDICAL GMBH (DE) | 2024-12-19 | — | — | WO | disclosed |
| EP-4477663-A1 | PROTEINS FOR ISOTHERMAL AMPLIFICATION | midge medical GmbH (DE) | 2024-12-18 | — | — | EP | disclosed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20230383338-A1 | ISOTHERMAL NUCLEIC ACID AMPLIFICATION METHODS FOR POINT-OF-NEED DIAGNOSIS | MIDGE MEDICAL GMBH (DE) | 2023-11-30 | — | — | US | disclosed |
| EP-4229218-A1 | ISOTHERMAL NUCLEIC ACID AMPLIFICATION METHODS FOR POINT-OF-NEED DIAGNOSIS | midge medical GmbH (DE) | 2023-08-23 | — | — | EP | disclosed |
| US-20220338519-A1 | ORAL SUPPLEMENTS CONTAINING ENRICHED PHENOLIC COMPOUND EXTRACTS COMBINED WITH ORGANIC ACID SODIUM SALTS, CREATINES AND/OR CREATINE SALTS | PHENOLICS, LLC (US) | 2022-10-27 | — | — | US | disclosed |
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3995592-A1 | MULTIMERIC ISOTHERMAL NUCLEIC ACID AMPLIFICATION METHODS FOR POINT-OF-NEED DIAGNOSIS | midge medical GmbH (DE) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022078775-A1 | ISOTHERMAL NUCLEIC ACID AMPLIFICATION METHODS FOR POINT-OF-NEED DIAGNOSIS | MIDGE MEDICAL GMBH (DE) | 2022-04-21 | — | — | WO | disclosed |
| EP-3985128-A1 | ISOTHERMAL NUCLEIC ACID AMPLIFICATION METHODS FOR POINT-OF-NEED DIAGNOSIS OF EMERGING INFECTIOUS DISEASES | midge medical GmbH (DE) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | MVD 2711/4885MEN1 501/4885LMNA 1628/4885 |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | MVD 2711/4885MEN1 501/4885LMNA 1628/4885 |
| US-11345693-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | MVD 2711/4885MEN1 501/4885LMNA 1628/4885 |
| US-12543767-B2 | Oral supplements containing enriched phenolic compound extracts combined with organic acid sodium salts, creatines and/or creatine salts | SLC22A8, SLC8B1, MCU | MVD 1763/4885MEN1 4244/4885LMNA 3744/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | MVD 2711/4885MEN1 501/4885LMNA 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.